Original Research ARTICLE
DC32, a Dihydroartemisinin Derivative, Ameliorates Collagen-induced Arthritis through an Nrf2-p62-Keap1 Feedback Loop
- 1China Pharmaceutical University, China
Artemisinins have been reported to have diverse functions, such as antimalaria, anticancer, anti-inflammation, and immunoregulation activities. DC32, a dihydroartemisinin derivative possessing potent immunosuppressive properties, was found in our previous study. In this study, the antirheumatic effect and underlying mechanisms of DC32 were investigated. The results showed that DC32 could markedly alleviate footpad inflammation, reduce cartilage degradation, activate the Nrf2/HO-1 signaling pathway, and increase the transcription of p62 in DBA/1 mice with collagen-induced arthritis (CIA). Further mechanistic exploration with NIH-3T3 cells indicated that DC32 could increase the transcription, expression and nuclear translocation of Nrf2. In addition, DC32 promoted degradation of Keap1 protein and upregulated HO-1 and p62 expression. Furthermore, the effect of DC32 on Keap1 degradation could be prevented by p62 knockdown using siRNA. Administration of DC32 could inhibit the phosphorylation of Akt/mTOR and ERK, and pretreatment of NIH-3T3 cells with the autophagy inhibitor 3-methyladenine (3-MA) attenuated the degradation of Keap1 induced by DC32. These results suggest that DC32 inhibits the degradation of Nrf2 by promoting p62-mediated selective autophagy and that p62 upregulation contributed to a positive feedback loop for persistent activation of Nrf2. In summary, our present study demonstrated that DC32 significantly suppressed rheumatoid arthritis (RA) via the Nrf2-p62-Keap1 feedback loop by increasing the mRNA and protein levels of Nrf2 and inducing p62 expression. These findings provide new mechanisms for artemisinins in RA treatment and a potential strategy for discovering antirheumatic drugs.
Keywords: DC32, rheumatoid arthritis (RA), collagen-induced arthritis (CIA), Nrf2-p62-Keap1 feedback loop, Keap1/Nrf2/HO-1 pathway
Received: 12 Sep 2018;
Accepted: 09 Nov 2018.
Edited by:Christoph Thiemermann, Queen Mary University of London, United Kingdom
Reviewed by:Sura Al Zoubi, Al-Balqa` Applied University, Jordan
Fausto Chiazza, Università degli Studi di Torino, Italy
Copyright: © 2018 Fan, Li, Yao, Liu, Liu and Yu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Prof. Ji-Hua Liu, China Pharmaceutical University, Nanjing, 210009, Jiangsu Province, China, email@example.com